

REC/1616  
IFW

Request  
For  
Continued Examination (RCE)  
Transmittal

Address to:  
Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

<i>Application Number</i>	09/180,132
<i>Filing Date</i>	May 24, 1999
<i>First Named Inventor</i>	Kim, Hyun K.
<i>Art Unit</i>	1616
<i>Examiner Name</i>	Barbara P. Radio
<i>Attorney Docket Number</i>	015280-261100

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).
- a.  Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.  
i.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_  
ii.  Other \_\_\_\_\_
- b.  Enclosed  
i.  Amendment/Reply  
ii.  Affidavit(s)/ Declaration(s)      iii.  Information Disclosure Statement (IDS)  
iv.  Other \_\_\_\_\_
2. **Miscellaneous**
- a.  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  
b.  Other \_\_\_\_\_
3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
- a.  The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 20-1430  
i.  RCE fee required under 37 CFR 1.17(e)  
ii.  Extension of time fee (37 CFR 1.136 and 1.17)  
iii.  Other \_\_\_\_\_
- b.  Check in the amount of \$ \_\_\_\_\_ enclosed  
c.  Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization of PTO-2038.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print /Type)	Eugenia Garrett-Makowski	Registration No. (Attorney/Agent)	37,330
Signature		Date	7/12/04

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print /Type)	Kimberly Rosa
Signature	

50258560 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On JULY 12, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Kimberly Rose

**PATENT**  
Attorney Docket No.: 015280-261100  
Client Ref. No.: E-016-96/2



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Hyun K. Kim *et al.*

Application No.: 09/180,132

Filed: May 24, 1999

For: 21-SUBSTITUTED  
PROGESTERONE DERIVATIVES AS  
NEW ANTI PROGESTATIONAL  
AGENTS

Customer No.: 20350

Confirmation No.

Examiner: Barbara P. Badio

Technology Center/Art Unit: 1616

**AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In connection with the Request For Continued Examination filed concurrently herewith, Applicants submit this Amendment. Applicants respectfully request reconsideration and further examination of the above-referenced patent application in view of the amendments and remarks presented herein.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 8 of this paper.